Evoq Remedies
EVOQREMEDIESLTD NSE
Evoq Remedies
Commercial ServicesNSE: EVOQREMEDIESLTD BSE: 543500 Trading & Distributors
Key Fundamentals
SMETrading & DistributorsCommercial ServicesMarket Cap
₹3.80 Cr
Volatility
Moderate
P/E Ratio
-15.4
EBITDA
₹-1.45 Cr
Return on Equity
0.2%
Debt to Equity
0
Book Value
₹17.79
EPS
₹0.18
52W High
₹6.11
52W Low
₹1.51
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company is almost debt free.
- Stock is trading at 0.08 times its book value
- Debtor days have improved from 160 to 55.1 days.
Weaknesses
5- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -11.2%
- Promoter holding is low: 0.02%
- Company has a low return on equity of 0.29% over last 3 years.
- Contingent liabilities of Rs.6.55 Cr.
Growth Rate
Revenue Growth
79.65% higher than
3Y
Net Income Growth
-340% lower than
3Y
Cash Flow Change
-375% lower than
3Y
ROE
-88.83% lower than
3Y
ROCE
-88.02% higher than
3Y
EBITDA Margin (Avg.)
-534% lower than
3Y
Quarterly Results
| Particulars | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.76 | 4.93 | 11.85 | 15.79 | 4.6 | 3.9 | 0.15 | 0 | 11.76 | 25.51 | 0 |
| Expenses | 1.71 | 4.2 | 11.12 | 15.48 | 8.64 | 3.83 | 1.87 | 1.63 | 12.36 | 26.46 | 0.5 |
| Operating Profit | 1.05 | 0.73 | 0.73 | 0.31 | -4.04 | 0.07 | -1.72 | -1.63 | -0.6 | -0.95 | -0.5 |
| OPM % | 38.04% | 14.81% | 6.16% | 1.96% | -87.83% | 1.79% | -1146.67% | — | -5.1% | -3.72% | — |
| Other Income | 0 | 0 | 0 | 0 | 6.02 | 0 | 2.26 | 0.01 | 2.4 | 1.06 | 0.19 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.04 | 0.03 | 0.02 |
| PBT | 1.05 | 0.73 | 0.73 | 0.31 | 1.98 | 0.07 | 0.54 | -1.62 | 1.76 | 0.08 | -0.33 |
| Tax % | 22.86% | 0% | 50.68% | 0% | 33.84% | 28.57% | 29.63% | 0% | 2.27% | 25% | -12.12% |
| Net Profit | 0.81 | 0.73 | 0.36 | 0.31 | 1.31 | 0.05 | 0.38 | -1.62 | 1.71 | 0.05 | -0.29 |
| EPS in Rs | 810 | 730 | 0.26 | 0.23 | 0.96 | 0.04 | 0.28 | -0.65 | 0.69 | 0.02 | -0.12 |
Profit & Loss
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3.25 | 9.07 | 10.02 | 16.78 | 20.39 | 4.05 | 11.76 | 25.51 |
| Expenses | 3.23 | 9.07 | 9.07 | 15.32 | 24.12 | 5.69 | 13.99 | 26.96 |
| Operating Profit | 0.02 | 0 | 0.95 | 1.46 | -3.73 | -1.64 | -2.23 | -1.45 |
| OPM % | 0.62% | 0% | 9.48% | 8.7% | -18.29% | -40.49% | -18.96% | -5.68% |
| Other Income | 0 | 0 | 0 | 0 | 6.02 | 2.26 | 2.41 | 1.25 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.05 | 0.05 |
| PBT | 0.02 | 0 | 0.95 | 1.46 | 2.29 | 0.61 | 0.13 | -0.25 |
| Tax % | 0% | — | 25.26% | 25.34% | 29.26% | 26.23% | 30.77% | -4% |
| Net Profit | 0.01 | 0 | 0.72 | 1.09 | 1.62 | 0.45 | 0.09 | -0.24 |
| EPS in Rs | 10 | 0 | 720 | 0.8 | 1.19 | 0.33 | 0.04 | -0.1 |
| Div. Payout % | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 13.6 | 13.6 | 13.6 | 24.9 | 24.9 |
| Reserves | 0.01 | 0.01 | 0.73 | 9.57 | 11.19 | 11.64 | 19.64 | 19.4 |
| Borrowings | 0 | 0.01 | 0 | 8.16 | 9.58 | 4.24 | 0 | 0.07 |
| Other Liabilities | 2.12 | 5.62 | 7.3 | 2 | 0.53 | 7.39 | 5.47 | 7.57 |
| Total Liabilities | 2.14 | 5.65 | 8.04 | 33.33 | 34.9 | 36.87 | 50.01 | 51.94 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.22 | 0.17 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.89 | 36.86 | 49.79 | 51.77 |
| Total Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.9 | 36.87 | 50.01 | 51.94 |
Cash Flow
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | 0.01 | -0.02 | 0.03 | -26.43 | -4.35 | 5.32 | -14.62 | -0.28 |
| Investing | 0 | 0 | 0 | 0 | -0.01 | -0.01 | -0.26 | 0 |
| Financing | 0 | 0 | 0 | 29.49 | 1.42 | -5.34 | 14.97 | 0.07 |
| Net Cash Flow | 0.01 | -0.02 | 0.03 | 3.06 | -2.94 | -0.03 | 0.09 | -0.21 |
| Free Cash Flow | 0.01 | -0.02 | 0.03 | -26.43 | -4.36 | 5.31 | -14.88 | -0.28 |
| CFO/OP | 50 | — | 3 | -1,785 | 99 | -334 | 654 | 19 |
Ratios
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 138 | 190 | 249 | 553 | 308 | 157 | 268 | 55.09 |
| Inventory Days | 3.39 | 2.42 | 6.97 | 20.66 | 38.33 | 732 | 61.9 | 23.92 |
| Days Payable | 240 | 227 | 315 | 32.05 | -10.2 | 767 | 97.59 | 10.89 |
| Cash Conversion Cycle | -98.04 | -34.3 | -59.11 | 541 | 357 | 122 | 232 | 68.12 |
| Working Capital Days | 1.12 | 1.21 | 26.23 | 437 | 441 | 2,263 | 1,369 | 631 |
| ROCE % | — | 0% | 246.75% | 9.11% | 6.97% | 1.91% | 0.35% | -0.56% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Evoq Remedies insights
54 extracted metrics + investor summaries across FY11–FY26.
Documents
1
Board Meeting Intimation for Intimation For Rescheduling Of Board Meeting From 14Th May, 2026 To 27Th May, 2026
9h - Board meeting rescheduled from 14 May 2026 to 27 May 2026 to consider audited FY2026 results. 9h - Board meeting rescheduled from 14 May 2026 to 27 May 2026 to consider audited FY2026 results.
2
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday, 14Th May, 2026
7 May - Board meeting on 14 May 2026 to approve audited half-year and year-end results for 31 March 2026. 7 May - Board meeting on 14 May 2026 to approve audited half-year and year-end results for 31 March 2026.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Evoq Remedies confirms it is not a Large Corporate; outstanding borrowing nil as of 31 March 2026. 30 Apr - Evoq Remedies confirms it is not a Large Corporate; outstanding borrowing nil as of 31 March 2026.
4
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Evoq Remedies confirms it is not a Large Corporate; outstanding borrowing nil as of 31 March 2026. 30 Apr - Evoq Remedies confirms it is not a Large Corporate; outstanding borrowing nil as of 31 March 2026.
Frequently Asked Questions about Evoq Remedies
What does Evoq Remedies Ltd do?
Incorporated in 2010, EVOQ Remedies Ltd is in the pharmaceutical business.[1]
Where is Evoq Remedies Ltd (543500) listed?
Evoq Remedies Ltd trades as EVOQREMEDIESLTD on the NSE and under code 543500 on the BSE.
Which sector does Evoq Remedies Ltd belong to?
Evoq Remedies Ltd is classified under the Commercial Services sector, in the Trading & Distributors industry.
What is the market capitalisation of Evoq Remedies Ltd?
Evoq Remedies Ltd has a market capitalisation of ₹3.8 Cr, which places it in the Small Cap band.
What is the PE ratio of Evoq Remedies Ltd?
Evoq Remedies Ltd trades at a PE ratio of -15.40, on earnings per share of ₹0.18, against a book value of ₹17.79 per share.
What is the 52-week high and low of Evoq Remedies Ltd?
Over the last 52 weeks Evoq Remedies Ltd has traded between ₹1.51 and ₹6.11.
What is the Return on Equity (ROE) of Evoq Remedies Ltd?
Evoq Remedies Ltd reported a return on equity of 0.20%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 2010, EVOQ Remedies Ltd is in the pharmaceutical business.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543500.md for Evoq Remedies Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.